# Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)

> **NCT01852604** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 143 (actual)

## Conditions studied

- Chronic Hepatitis C Virus

## Interventions

- **DRUG:** Samatasvir
- **DRUG:** Simeprevir
- **DRUG:** Ribavirin (RBV)
- **DRUG:** TMC647055
- **DRUG:** Ritonavir (RTV)
- **BIOLOGICAL:** Pegylated interferon (Peg-IFN)
- **OTHER:** Samatasvir matching placebo

## Key facts

- **NCT ID:** NCT01852604
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2015-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01852604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01852604, "Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01852604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*